It’s time to jump back into Viking Therapeutics (VKTX).

Now trading at $26.50, VKTX could explode higher again.

That is, if the company sees further positive results with its obesity trials. 

Most recently, VKTX initiated its VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. All as the company progresses with both oral and subcutaneous formulations for the potential treatment.

Also, according to Brian Lian, Ph.D., CEO of Viking.  “Along with the successful initiation of the Phase 3 program we continue to make progress on VK2735’s broader development.  This includes our plans to initiate an additional clinical study to evaluate a monthly maintenance regimen, which is expected to begin later this year.  We also continue to build on the encouraging early data reported for the oral tablet formulation of VK2735 and expect to report the results of the Phase 2 VENTURE-Oral Dosing study in the second half of this year.” 

Also, there are still rumors that a company like Pfizer could potentially buy a company like this one. Especially after PFE CEO Albert Bourla said the company could seek deals to add obesity therapies to strengthen its pipeline.

Sincerely,

Ian Cooper